<DOC>
	<DOCNO>NCT01223833</DOCNO>
	<brief_summary>The Logribmet study prospective study evaluate grip strength change hand postmenopausal woman breast cancer receive treatment tamoxifen aromatase inhibitor . Patients include study undergo grip strength measurement receive rheumatological questionnaire prior start treatment , 3 6 month year 1 therapy . Furthermore , BMI measure assess BMI predictor decrease grip strength . IGF-I , GH IGFBP-3 serum level also measure time point .</brief_summary>
	<brief_title>A Prospective Assessment Loss Grip Strength Baseline BMI Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors Tamoxifen</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Patients early breast cancer schedule receive endocrine therapy tamoxifen thirdgeneration aromatase inhibitor , anastrozole , letrozole exemestane . 2 . No major rheumatological disorder severe rheumatoid arthritis . 3 . Patients must provide informed consent participation study . 1 . Concomitant endocrine therapy breast cancer . 2 . Concomitant intake sex hormone contain drug hormone replacement therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>arthralgia</keyword>
	<keyword>IGF-I</keyword>
	<keyword>BMI</keyword>
	<keyword>grip strength</keyword>
</DOC>